Trexquant Investment LP Takes $2.25 Million Position in Eli Lilly And Co (NYSE:LLY)

Trexquant Investment LP acquired a new stake in shares of Eli Lilly And Co (NYSE:LLY) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,221 shares of the company’s stock, valued at approximately $2,250,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Eli Lilly And Co by 5.6% during the first quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. Capital International Investors raised its holdings in shares of Eli Lilly And Co by 3.6% in the 4th quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock worth $3,424,531,000 after acquiring an additional 910,672 shares during the last quarter. FMR LLC raised its holdings in shares of Eli Lilly And Co by 6.7% in the 4th quarter. FMR LLC now owns 14,235,227 shares of the company’s stock worth $1,870,935,000 after acquiring an additional 888,413 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Eli Lilly And Co by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 12,377,007 shares of the company’s stock worth $1,623,438,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Eli Lilly And Co by 125.9% in the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock worth $1,413,841,000 after acquiring an additional 5,679,574 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

A number of research firms recently weighed in on LLY. Morgan Stanley lowered shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a report on Sunday, April 19th. Cowen upped their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Mizuho upped their target price on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Cfra upped their target price on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, Goldman Sachs Group upgraded shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price on the stock in a report on Wednesday, March 11th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $158.64.

In related news, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the completion of the transaction, the senior vice president now directly owns 44,773 shares of the company’s stock, valued at approximately $6,274,935.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 12,663 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $163.60, for a total transaction of $2,071,666.80. Following the completion of the transaction, the insider now directly owns 112,197,641 shares of the company’s stock, valued at $18,355,534,067.60. The disclosure for this sale can be found here. Insiders have sold a total of 906,320 shares of company stock valued at $132,984,238 over the last three months. Insiders own 0.09% of the company’s stock.

Eli Lilly And Co stock opened at $151.16 on Friday. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $164.90. The firm has a 50 day moving average price of $152.85 and a 200-day moving average price of $136.00. The company has a market capitalization of $145.65 billion, a P/E ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The firm had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same period in the prior year, the firm earned $1.33 EPS. The company’s revenue was up 15.1% compared to the same quarter last year. Equities analysts expect that Eli Lilly And Co will post 6.81 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date of this dividend is Thursday, May 14th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Why do companies engage in swaps?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News